Breaking News Instant updates and real-time market news.

WAB

Wabtec

$71.90

-4.67 (-6.10%)

12:00
04/25/19
04/25
12:00
04/25/19
12:00

Downside put buy in Wabtec as shares wobble after earnings

Downside put buy in Wabtec as shares wobble after earnings. The stock down 5.8% to $72.16 and small lots of Oct 65 puts trade $3.20 to $3.40 before a 3.2K lot prints $3.45. 5.8K trade total and, with 1.3K already open at that line, today's put buying is on track to create the largest open interest in the name, next to the 5.9K open at the May 65 put strike. The 65-strike is 1.9% from late-December 52-week lows of $66.28. The October contract captures the next earnings in April and a report in July as well.

  • 25

    Apr

  • 08

    May

  • 21

    May

  • 05

    Jun

  • 13

    Nov

WAB Wabtec
$71.90

-4.67 (-6.10%)

01/28/19
GDHS
01/28/19
NO CHANGE
Target $7
GDHS
Underperform
GE could shift to GAAP accounting, causing stock drop, says Gordon Haskett
New General Electric (GE) CEO Larry Culp likely has every intention of establishing a 2019 guidance framework that the company can actually achieve, which would be welcomed by investors after years of "non-credible GE guidance, perpetual exaggerations, opaque disclosure and aggressive accounting," Gordon Haskett analyst John Inch told investors earlier in a research note titled "Move to GAAP could drive stock hit." The analyst has an Underperform rating on General Electric with a $7 price target. The stock in morning trading is down 33c to $8.83. He believes Larry Culp, in contrast with previous CEO John Flannery, is going to want to set a guidance bar that GE "can at least hit." In turn, while GE may not be able to adopt more conservative accounting while under government investigation, a move to GAAP would at least demonstrate Culp's directional willingness to abandon the "inflated and exaggerated earnings presentation practices of the past," says Inch. However, if GE were to move to GAAP accounting, its share price would move lower, driven by a lower GAAP impact on consensus, the analyst contends. Further, GE's accounting could still be viewed as aggressive under a GAAP presentation framework, adds Inch. As such, he thinks subsequent future restatements from the adoption of more conservative accounting "could readily ensue." Inch also sees risks in GE's revised deal with Wabtec deal (WAB).
02/22/19
JEFF
02/22/19
INITIATION
Target $80
JEFF
Hold
Wabtec initiated with a Hold at Jefferies
Jefferies analyst Saree Boroditsky started Wabtec (WAB) with a Hold rating and $80 price target. The analyst views Wabtec as a "solid" long-term industrial, but is cautious on entering the stock given the potential negative impact on equipment demand from Precision Scheduled Railroading adoption and the "technical overhang" created by the GE (GE) Transportation merger closing next week.
02/22/19
02/22/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Nvidia (NVDA) initiated with an Overweight at Atlantic Equities. 2. United Technologies (UTX) resumed with an Overweight at JPMorgan. 3. Wabtec (WAB) initiated with a Hold at Jefferies. 4. STMicroelectronics (STM) initiated with an Outperform at Cowen. 5. Biogen (BIIB) initiated with a Market Perform at BMO Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/26/19
UBSW
02/26/19
NO CHANGE
Target $13
UBSW
Buy
UBS boosts General Electric target to $13, sees fading leverage concerns
UBS analyst Peter Lennox-King raised his price target for General Electric (GE) to $13 from $12 and keeps a Buy rating on the shares. The stock closed yesterday up 6%, or 65c, to $10.82. With net proceeds of $20.5B from the BioPharma unit sale to Danaher (DHR), $2.9B in cash from Wabtec (WAB), $3.8B in new Wabtec shares, and $13B in Baker Hughes (BHGE) shares, GE has assets "well beyond" the $30B of Industrial debt reduction targeted last month, Lennox-King tells investors in a research note. This comes while the company retains ownership of ~$3B in Healthcare EBITDA, adds the analyst, who now could even envision a scenario of year-end 2020 leverage of below two times. As leverage concerns fade, Lennox-King expects investor focus to shift to GE's "fundamental turnaround."

TODAY'S FREE FLY STORIES

BAX

Baxter

$81.35

0.79 (0.98%)

05:52
06/20/19
06/20
05:52
06/20/19
05:52
Recommendations
Baxter analyst commentary  »

Baxter price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 16

    Sep

SHOP

Shopify

$327.40

23.09 (7.59%)

05:48
06/20/19
06/20
05:48
06/20/19
05:48
Recommendations
Shopify analyst commentary  »

Shopify price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

COMM

CommScope

$15.62

-0.265 (-1.67%)

05:41
06/20/19
06/20
05:41
06/20/19
05:41
Upgrade
CommScope rating change  »

CommScope upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jun

TEL

TE Connectivity

$93.39

0.67 (0.72%)

05:40
06/20/19
06/20
05:40
06/20/19
05:40
Upgrade
TE Connectivity rating change  »

TE Connectivity upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JWN

Nordstrom

$33.18

1.04 (3.24%)

05:37
06/20/19
06/20
05:37
06/20/19
05:37
Upgrade
Nordstrom rating change  »

Nordstrom upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

PGSVY

PGS ASA

$0.00

(0.00%)

05:33
06/20/19
06/20
05:33
06/20/19
05:33
Downgrade
PGS ASA rating change  »

PGS ASA downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PDD

Pinduoduo

$20.96

0.08 (0.38%)

05:32
06/20/19
06/20
05:32
06/20/19
05:32
Initiation
Pinduoduo initiated  »

Pinduoduo initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CB

Chubb

$148.73

1.37 (0.93%)

05:30
06/20/19
06/20
05:30
06/20/19
05:30
Downgrade
Chubb rating change  »

Chubb downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

OPHLY

Ono Pharmaceutical

$0.00

(0.00%)

05:29
06/20/19
06/20
05:29
06/20/19
05:29
Downgrade
Ono Pharmaceutical rating change  »

Ono Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YARIY

Yara

$0.00

(0.00%)

05:27
06/20/19
06/20
05:27
06/20/19
05:27
Downgrade
Yara rating change  »

Yara downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZURVY

Zurich Insurance

$0.00

(0.00%)

05:26
06/20/19
06/20
05:26
06/20/19
05:26
Upgrade
Zurich Insurance rating change  »

Zurich Insurance upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRE

Bank of Ireland

$0.00

(0.00%)

05:24
06/20/19
06/20
05:24
06/20/19
05:24
Upgrade
Bank of Ireland rating change  »

Bank of Ireland upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DOC

Physicians Realty Trust

$18.27

0.095 (0.52%)

05:23
06/20/19
06/20
05:23
06/20/19
05:23
Initiation
Physicians Realty Trust initiated  »

Physicians Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HTA

Healthcare Trust

$29.18

0.16 (0.55%)

05:23
06/20/19
06/20
05:23
06/20/19
05:23
Initiation
Healthcare Trust initiated  »

Healthcare Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

HR

Healthcare Realty Trust

$33.14

0.26 (0.79%)

05:22
06/20/19
06/20
05:22
06/20/19
05:22
Initiation
Healthcare Realty Trust initiated  »

Healthcare Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

SCRYY

Scor

$0.00

(0.00%)

05:22
06/20/19
06/20
05:22
06/20/19
05:22
Upgrade
Scor rating change  »

Scor upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMS

Fresenius Medical

$39.49

1.175 (3.07%)

05:20
06/20/19
06/20
05:20
06/20/19
05:20
Upgrade
Fresenius Medical rating change  »

Fresenius Medical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPQ

HP Inc.

$20.63

0.1 (0.49%)

05:16
06/20/19
06/20
05:16
06/20/19
05:16
Initiation
HP Inc. initiated  »

Deutsche Bank starts HP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 01

    Jul

  • 02

    Jul

  • 03

    Jul

  • 04

    Jul

DELL

Dell Technologies

$53.39

1.88 (3.65%)

05:15
06/20/19
06/20
05:15
06/20/19
05:15
Initiation
Dell Technologies initiated  »

Deutsche Bank starts Dell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

FNMA

Fannie Mae

05:12
06/20/19
06/20
05:12
06/20/19
05:12
Initiation
Fannie Mae initiated  »

Fannie Mae initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMCC

Freddie Mac

$0.00

(0.00%)

05:12
06/20/19
06/20
05:12
06/20/19
05:12
Initiation
Freddie Mac initiated  »

Freddie Mac initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$197.87

-0.65 (-0.33%)

05:12
06/20/19
06/20
05:12
06/20/19
05:12
Initiation
Apple initiated  »

Deutsche Bank, fearing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JBLU

JetBlue

$19.05

-0.21 (-1.09%)

05:07
06/20/19
06/20
05:07
06/20/19
05:07
Recommendations
JetBlue analyst commentary  »

JetBlue price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VYGR

Voyager Therapeutics

$27.87

0.05 (0.18%)

, SNY

Sanofi

$44.11

0.99 (2.30%)

05:05
06/20/19
06/20
05:05
06/20/19
05:05
Recommendations
Voyager Therapeutics, Sanofi, Neurocrine analyst commentary  »

Voyager Therapeutics…

VYGR

Voyager Therapeutics

$27.87

0.05 (0.18%)

SNY

Sanofi

$44.11

0.99 (2.30%)

NBIX

Neurocrine

$85.47

-0.28 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 16

    Sep

ORCL

Oracle

$52.69

-0.19 (-0.36%)

05:02
06/20/19
06/20
05:02
06/20/19
05:02
Recommendations
Oracle analyst commentary  »

Oracle price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.